Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.07 · 8-K

Bone Biologics Corp

BBLGNASDAQEQUITYCurrent

Submission of Matters to a Vote of Security Holders

Item Submission 5.07 of Matters to a Vote of Security Holders. At the Annual Meeting of stockholders (the “Annual Meeting”) of Bone Biologics Corporation (the “Company”), held on September 28, 2026, the Company’s stockholders voted on the matters described below. The number of shares of common stock entitled to vote at the Annual Meeting was 2,011,057.…

Filed Sep 29, 2026Accepted Sep 29, 2026, 5:00 PM EDTCIK 1419554Accession 0001493152-26-044889
Share

Company context

We are a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (“DBM”) is an osteopromotive recombinant protein that provides target specific control over bone regeneration. The NELL-1 technology platform has been licensed exclusively for worldwide applications to us through a technology transfer from the UCLA Technology Development Group on behalf of UC Regents (“UCLA TDG”). UCLA TDG and the Company received guidance from the U.S. Food and Drug Administration (“FDA”) that NELL-1/DBM will be classified as a device/drug combination product that will require an FDA-approved pre-market approval (“PMA”) application before it can be commercialized in the United States.

Current securities

Historical securities (5)

Recent company filings

  1. 10-Q filingOct 26, 2026
  2. 25-NSE - filed by Nasdaq Stock Market LLC regarding Bone Biologics CorpOct 13, 2026
  3. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingSep 16, 2026
  4. DEF 14A filingAug 28, 2026
  5. PRE 14A filingAug 18, 2026

Registered securities in this filing

BONE BIOLOGICS CORPORATION · 8-K · Filed 2026-09-29

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.001 per share

Symbol
BBLG
Exchange
NASDAQ
Classification
COMMON
Filing context

Context: From2026-09-282026-09-28_custom_CommonStockParValue0.001PerShareMember

Dimensions: us-gaap:StatementClassOfStockAxis

Warrants to Purchase Common Stock, par value $0.001 per share

Symbol
BBLGW
Exchange
NASDAQ
Classification
WARRANT
Status
Historical · closed Oct 12, 2026
Filing context

Context: From2026-09-282026-09-28_custom_WarrantsToPurchaseCommonStockParValue0.001PerShareMember

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000149315226044889 · 2 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 5.07

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.07Item 5.07 - Submission of Matters to Vote
Item Submission 5.07 of Matters to a Vote of Security Holders. At the Annual Meeting of stockholders (the “Annual Meeting”) of Bone Biologics Corporation (the “Company”), held on September 28, 2026, the Company’s stockholders voted on the matters described below. The number of shares of common stock entitled to vote at the Annual Meeting was 2,011,057. The number of shares of common stock present or represented by proxy at the Annual Meeting was 951,746. The voting results for the proposals are as follows: Proposal 1. The Company’s stockholders elected the following four director nominees to serve until the date of the next Annual Meeting of stockholders following the date such persons are elected as directors, and until their successors are duly elected and qualified. The results of the vote are summarized in the table below. Director Votes Votes Broker Nominees For Withheld Non-Votes ────────────────────────────────────────────────────── Bruce 152,615 3,941 758,866 Stroever Siddhesh 155,570 3,842 758,866 Angle Robert 158,799 3,892 758,866 Gagnon Philip 158,783 3,891 758,866 Meikle Proposal 2. The Company’s stockholders approved, on an advisory basis, the Company’s executive compensation. The results of the vote are summarized in the table below. Votes Votes Abstentions Broker For Against Non-Votes ──────────────────────────────────────────────────────── 139,592 49,851 3,437 758,866 Proposal 3. The Company’s stockholders ratified the appointment of Weinberg & Company, P.A. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the vote are summarized in the table below. Votes Votes Abstentions For Against ───────────────────────────────────────── 898,011 49,834 3,901 Proposal 4. The Company’s stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the potential issuance of shares of the Company’s common stock underlying certain warrants issued by us pursuant to that certain Securities Purchase Agreement, dated as of July 7, 2026, by and among the Company and the investor named on the signatory pages thereto, and that certain Engagement Letter, by and among the Company and H.C. Wainwright & Co., LLC, dated as of March 11, 2025, as amended, in an amount equal to or in excess of 20% of the Company’s common stock outstanding immediately prior to the issuance of such warrants. The results of the vote are summarized in the table below. Votes Votes Abstentions Broker For Against Non-Votes ──────────────────────────────────────────────────────── 147,340 42,233 3,307 758,866 Proposal 5. The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of its outstanding common stock in a range of not less than 1-for-2 but not more than 1-for-10, at the discretion of the board of directors. The results of the vote are summarized in the table below. Votes Votes Abstentions For Against ───────────────────────────────────────── 806,603 137,720 7,423 Proposal 6. The Company’s stockholders approved a proposal to adjourn the Annual Meeting, if necessary or appropriate, if there are not sufficient votes at the time of the Annual Meeting to approve the proposals submitted to the Company’s stockholders and/or establish a quorum for the Annual Meeting. The results of the vote are summarized in the table below. Votes Votes Abstentions For Against ───────────────────────────────────────── 806,477 137,919 7,350 Broker non-votes represent shares held by broker nominees for beneficial owners that were not voted because the broker nominee did not receive voting instructions from the beneficial owner and lacked discretionary authority to vote the shares on a non-routine proposal. Because Proposals 1, 2, 3, 4 and 5 were approved by the Company’s stockholders, an adjournment of the Annual Meeting was not necessary.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.